欧洲临床试验成像市场 – 行业趋势和 2029 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 免费样本报告 免费样本报告 购买前请咨询 提前咨询 立即购买 立即购买

欧洲临床试验成像市场 – 行业趋势和 2029 年预测

  • Healthcare
  • Published Report
  • Sep 2022
  • Europe
  • 350 页面
  • 桌子數: 173
  • 图号: 44
  • Author : Sachin Pawar

通过敏捷供应链咨询解决关税挑战

供应链生态系统分析现已成为 DBMR 报告的一部分

欧洲临床试验成像市场,按产品和服务(服务和软件)、方式(计算机断层扫描、磁共振成像、超声心动图、核医学、正电子发射断层扫描、X 射线、超声波、光学相干断层扫描等)、应用(肿瘤学、神经病学、内分泌学、心脏病学、皮肤病学、血液学等)、最终用户(制药和生物技术公司、合同研究组织、医疗器械制造商、学术和政府研究机构等)、分销商(直销和招标销售)划分 - 行业趋势和预测到 2029 年。

Clinical Trial Imaging Market

欧洲临床试验成像市场分析与洞察

成像技术的需求不断增加,老年人口增加导致慢性病患病率上升,以及市场参与者采取的产品发布、进步、收购和协议等战略举措,都是预计推动市场增长的因素。

Clinical Trial Imaging Market

Clinical Trial Imaging Market

然而,成像设备的不适当和不利的报销情形以及临床试验成像仪器缺乏明确的标准预计会抑制市场的增长。

用于诊断和治疗慢性疾病的临床试验成像技术不断进步,预计将推动市场增长。Data Bridge Market Research 分析称,在 2022 年至 2029 年的预测期内,欧洲临床试验成像市场将以 7.9% 的复合年增长率增长。

报告指标

细节

预测期

2022 至 2029 年

基准年

2021

历史岁月

2020 (可定制至 2019-2014)

定量单位

收入(百万美元)和定价(美元)

涵盖的领域

按产品和服务(服务和软件)、模式(计算机断层扫描、磁共振成像、超声心动图、核医学、正电子发射断层扫描、X 射线、超声波、光学相干断层扫描等)、应用(肿瘤学、神经病学、内分泌学、心脏病学、皮肤病学、血液学等)、最终用户(制药和生物技术公司、合同研究组织、医疗器械制造商、学术和政府研究机构等)、分销商(直销和招标销售)

覆盖国家

德国、法国、英国、意大利、西班牙、俄罗斯、土耳其、比利时、荷兰、瑞士、欧洲其他地区

涵盖的市场参与者

Navitas Life Sciences、Resonance Health Analytical Services、BioTelemetry(飞利浦公司旗下子公司)、IXICO plc、ICON plc、anagram 4 clinical trials、Quotient Sciences、WORLDCARE CLINICAL、Clario、Paraxel International Corporation、Median Technologies、Perspectum、Calyx、WIRB-Copernicus Group 和 Invicro.LLC 等

市场定义

临床试验是开发新药的过程。它旨在研究潜在的治疗及其对人类的影响。在新药商业化之前,会进行广泛的临床试验以识别有希望的化合物,并进行安全测试以确定可能的风险。

在临床试验中,医学成像在获得更准确、更有效的结果方面发挥着重要作用。可以使用不同的成像技术来阐明和展示药物的机械作用。临床试验成像是通过创建身体内部图像表示来进行临床分析和医疗干预的过程。它有几种不同的技术,用于观察人体以监测、治疗和诊断医疗状况。

在不久的将来,与药物发现的临床试验成像相关的重要决策将由那些不仅了解活检而且还能使用临床试验成像工具及其发布的知识来制定假设和确定质量目标的个人做出。

欧洲临床试验成像市场动态

驱动程序

  • 制药和成像行业的增长

制药和成像行业进行临床试验以评估药物开发的安全性和有效性。它们是增长最快的行业之一。目前,生物制药的年增长率超过 8%,是传统制药的两倍,预计在可预见的未来将继续保持这一增长速度。新药开发在制药和成像公司中得到广泛应用,因为它们是最注重研究的行业之一。

许多制药公司正在不断提高其开发流程的效率,以降低与新药开发流程相关的成本。许多制药公司越来越希望整合与其合作的外包供应商的数量,并与有限数量的外包供应商达成许多战略合作安排。一些制药公司已经达成合作开发新药。制药公司之间合作数量的增加为研究带来了巨大的机会。

不同类型的合作和协议促进了制药和成像行业的增长,从而推动了市场增长。

  • 研发支出不断增加

影像和制药公司不断投资研发,为客户提供临床试验影像创新服务,并提升其市场占有率。医学影像在临床开发中发挥着重要作用。尽管医学影像行业由于新技术在市场上的实施而处于不断波动的状态,但制药和影像行业仍在不断增长。这归因于对医学影像公司的投资增加、并购以及采用影像技术创新来支持医疗器械的临床试验。制药和生物技术公司增加研发支出正在推动市场增长。

这促进了生物制药行业组织新产品和高研究导向项目的开发,以及对人类基因组研究的高度偏好。研发支出的增加也促进了治疗慢性疾病的新药和新疗法的开发,从而促进了市场的增长。这有助于制药和生物技术公司在成像临床试验类别中开发新技术,因此,研发支出的增加预计将推动市场增长。

机会

  • 医疗支出增加

随着各国人民的可支配收入不断提高,全球医疗支出也随之增加。此外,为满足人口需求,政府机构和医疗机构正通过加快医疗支出来发挥主动作用。

例如,

  • 2020 年 10 月,欧洲医疗技术组织 (MedTech Europe Organization) 的报告指出,2020 年欧洲整体医疗支出占 GDP 的约 10%,而 2019 年为 GDP 的 8.3%,其中 76.6% 用于住院和门诊护理

医疗支出的增长也有利于经济和医疗保健领域的进一步增长,而且它的主要成果是它显著影响了市场上更好、更先进的医疗产品的开发。因此,医疗支出的激增对市场来说是一个更大的机会。

  • 市场参与者的战略举措

由于研发水平的提高以及临床试验成像市场的增长以及对创新药物的需求,市场对临床试验成像的需求正在增加。因此,顶级市场参与者实施了一项新战略,通过开发新产品并与其他市场参与者合作来改善业务运营和盈利能力。

例如,

  • 2020 年 2 月,ICON plc 收购了欧洲医疗器械 CRO、报销和监管咨询公司 MedPass International。据报道,此次收购有助于 ICON 在欧洲扩大医疗器械和诊断研究服务。

市场参与者的这些战略举措,包括收购、会议和重点细分产品发布,正在帮助他们发展和改善公司的产品组合,最终带来更多收入。因此,市场参与者的这些战略举措可能成为市场增长的机会。

  • 高风险辐射致病

在临床医学成像中,辐射会被人体吸收,从而损害患者体内的分子结构。高剂量的辐射会影响人体细胞,包括脱发、皮肤烧伤和癌症发病率增加。在 CT 扫描中接受 10 mSv 辐射剂量后,患上致命癌症的风险估计为 2000 分之一。

例如,

  • 根据美国放射学会 (RSNA) 的数据,美国 1% 至 2% 的癌症是由 CT 扫描引起的,美国癌症协会将 CT 扫描和 X 射线确定为乳腺癌、脑癌和其他癌症的原因之一
  • 据美国疾病控制与预防中心称,暴露于高剂量辐射会导致急性辐射综合症。人体吸收的辐射量称为辐射剂量。

发生的高风险辐射会降低临床试验成像设备的使用和销售,从而影响参与该市场的制造商的信誉。因此,预计高风险辐射致病将抑制市场增长。

  • 严格的监管政策

医疗保健行业受到广泛而复杂的法律和法规体系的监管。

例如,

  • 2018 年 4 月,美国 FDA 发布了最新的《临床试验影像终点流程标准指南》,其中包括临床试验中获得的影像数据的质量
  • 生物科技和制药行业需要首先获得 FDA 的药物开发批准。在开始临床研究之前,他们必须向 FDA 提交新药临床试验 (IND) 申请。

COVID-19 对欧洲临床试验成像市场的影响

诊断成像服务耗时且复杂,因为需要制定严格的感染控制和预防措施来控制传播风险并保护医护人员。因此,是否对疑似患者或 COVID-19 阳性患者进行成像取决于其对患者状况改善的影响。

2020 年 4 月,GDP 较低的欧洲国家减少了心脏影像检查,以防止其医疗系统不堪重负。除了取消非紧急检查的政策外,其他重要因素也可能导致影像检查的执行率下降,例如患者在 COVID-19 大流行期间无法或不愿寻求医疗建议。这些因素包括恐惧、避免潜在感染的愿望、公共交通和其他基本腋窝服务等。这似乎是大流行期间非 COVID-19 疾病的医疗效用降低的一般模式的一部分。

最新动态

  • 2022 年 1 月,Clario 与放射性药物生产和正电子发射断层扫描 (PET) 收购公司 XingImaging 合作,在中国开展 PET 成像临床试验,以测试新型疗法。此次合作旨在共享 Clario 和 XingImaging 的联合资源和神经科学专家,以加快在中国开展临床试验和药物研发。
  • 2021 年 11 月,Clario 成立。ERT 和 Bioclinica 合并成立 Clario。新公司的成立导致临床成像软件和服务的分销和销售额的上升。

欧洲临床试验成像市场范围

欧洲临床试验成像市场根据产品和服务、模式、应用、最终用户和分销商分为五个部分。这些部分之间的增长将帮助您分析行业中增长微弱的部分,并为用户提供有价值的市场概览和市场洞察,帮助他们做出战略决策,确定核心市场应用。

產品與服務

  • 服务
  • 软件

根据产品和服务,市场分为服务和软件。

情态

  • 计算机断层扫描
  • 磁共振成像
  • 超声心动图
  • 核医学
  • 正电子发射断层扫描
  • X 射线
  • 超声波
  • 光学相干断层扫描
  • 其他的

根据模式,市场分为计算机断层扫描磁共振成像、超声心动图、核医学、正电子发射断层扫描、X射线、超声波、光学相干断层扫描等。

应用

  • 肿瘤学
  •  神经病学
  •  心脏病学
  •  内分泌学
  •  皮肤科
  •  血液学
  •  其他的

根据应用,市场分为肿瘤学、神经病学、心脏病学、内分泌学、皮肤病学、血液学和其他。

最终用户

  • 合同研究组织
  • 制药及生物技术公司
  • 医疗器械制造商
  • 学术和政府研究机构
  • 其他的

根据最终用户,市场分为合同研究组织、制药和生物技术公司、医疗设备制造商、学术和政府研究机构等。

分销商

  • 直销
  •  招标销售

Clinical Trial Imaging Market

Based on distributor, the market is segmented into direct sales and tender sales.

Europe Clinical Trial Imaging Market Regional Analysis/Insights

Europe clinical trial imaging market is analyzed, and market size insights and trends are provided by regions, product and services, modality, application, end user, and distributor as referenced above.

The countries covered in this market report are Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, rest of Europe. Germany is expected to dominate the market since clinical imaging market in Germany is the single largest market in Europe, and proficient to accumulate innovative medical imaging technologies. At the same time, the high number of well-qualified users provides a powerful platform for the further development of medical imaging technologies.

The country section of the report also provides individual market-impacting factors and changes in regulations in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of European brands and their challenges faced due to large or scarce competition from local and domestic brands impact on sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Europe Clinical Trial Imaging Market Share Analysis

The Europe clinical trial imaging market competitive landscape provides details on the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, the Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the Europe clinical trial imaging market.

Some of the major players operating in the market are Navitas Life Sciences, Resonance Health Analytical Services, BioTelemetry, a Philips Company, IXICO plc, ICON plc, anagram 4 clinical trials, Quotient Sciences,WORLDCARE CLINICAL, Clario, Paraxel International Corporation, Median Technologies, Perspectum, Calyx, WIRB-Copernicus Group, and Invicro.LLC among others.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE CLINICAL TRIAL IMAGING MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCTS AND SERVICES LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

5 EUROPE CLINICAL TRIAL IMAGING MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING R&D EXPENDITURE

6.1.2 INCREASING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS (CROS)

6.1.3 INCREASING INCIDENCE OF CHRONIC DISEASES

6.1.4 GROWTH IN THE PHARMACEUTICAL AND IMAGING INDUSTRIES

6.2 RESTRAINTS

6.2.1 HIGH-RISK RADIATION CAUSING DISEASES

6.2.2 HIGH IMPLEMENTATION COST OF IMAGING SYSTEMS

6.3 OPPORTUNITIES

6.3.1 RISE IN HEALTHCARE EXPENDITURE

6.3.2 STRATEGIC INITIATIVES BY KEY PLAYERS

6.3.3 DEVELOPMENT OF INNOVATIVE IMAGING MODALITIES AND CONTRAST AGENTS

6.4 CHALLENGES

6.4.1 STRICT REGULATORY POLICIES

6.4.2 COST OF CLINICAL TRIALS

7 EUROPE CLINICAL TRIAL IMAGING MARKET, BY PRODUCTS & SERVICES

7.1 OVERVIEW

7.2 SERVICES

7.2.1 OPERATIONAL IMAGING SERVICES

7.2.2 READ ANALYSIS SERVICES

7.2.3 TRIAL DESIGN CONSULTING SERVICES

7.2.4 SYSTEM AND TECHNICAL SUPPORT SERVICES

7.3 SOFTWARE

8 EUROPE CLINICAL TRIAL IMAGING MARKET, BY MODALITY

8.1 OVERVIEW

8.2 COMPUTED TOMOGRAPHY

8.3 MAGENTIC RESONANCE IMAGING

8.4 ECHOCARDIOGRAPHY

8.5 NUCLEAR MEDICINE

8.6 POSITRON EMISSION TOMOGRAPHY

8.7 X-RAY

8.8 ULTRASOUND

8.9 OPTICAL COHERENCE TOMOGRAPHY

8.1 OTHERS

9 EUROPE CLINICAL TRIAL IMAGING MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 ONCOLOGY

9.2.1 X-RAY

9.2.2 ULTRASOUND

9.2.3 COMPUTED TOMOGRAPHY

9.2.4 MAGNETIC RESONANCE IMAGING

9.2.5 NUCLEAR MEDICINE

9.2.6 POSITRON EMISSION TOMOGRAPHY

9.2.7 OPTICAL COHERENCE TOMOGRAPHY

9.2.8 ECHOCARDIOGRAPHY

9.2.9 OTHERS

9.3 NEUROLOGY

9.3.1 COMPUTED TOMOGRAPHY

9.3.2 MAGNETIC RESONANCE IMAGING

9.3.3 POSITRON EMISSION TOMOGRAPHY

9.3.4 NUCLEAR MEDICINE

9.3.5 X-RAY

9.3.6 ULTRASOUND

9.3.7 OPTICAL COHERENCE TOMOGRAPHY

9.3.8 ECHOCARDIOGRAPHY

9.3.9 OTHERS

9.4 CARDIOLOGY

9.4.1 ECHOCARDIOGRAPHY

9.4.2 MAGNETIC RESONANCE IMAGING

9.4.3 COMPUTED TOMOGRAPHY

9.4.4 POSITRON EMISSION TOMOGRAPHY

9.4.5 NUCLEAR MEDICINE

9.4.6 X-RAY

9.4.7 ULTRASOUND

9.4.8 OPTICAL COHERENCE TOMOGRAPHY

9.4.9 OTHERS

9.5 ENDOCRINOLOGY

9.5.1 COMPUTED TOMOGRAPHY

9.5.2 MAGNETIC RESONANCE IMAGING

9.5.3 ECHOCARDIOGRAPHY

9.5.4 POSITRON EMISSION TOMOGRAPHY

9.5.5 NUCLEAR MEDICINE

9.5.6 X-RAY

9.5.7 ULTRASOUND

9.5.8 OPTICAL COHERENCE TOMOGRAPHY

9.5.9 OTHERS

9.6 DERMATOLOGY

9.6.1 ULTRASOUND

9.6.2 X-RAY

9.6.3 MAGNETIC RESONANCE IMAGING

9.6.4 COMPUTED TOMOGRAPHY

9.6.5 OPTICAL COHERENCE TOMOGRAPHY

9.6.6 POSITRON EMISSION TOMOGRAPHY

9.6.7 NUCLEAR MEDICINE

9.6.8 ECHOCARDIOGRAPHY

9.6.9 OTHERS

9.7 HEMATOLOGY

9.7.1 ULTRASOUND

9.7.2 COMPUTED TOMOGRAPHY

9.7.3 MAGNETIC RESONANCE IMAGING

9.7.4 X-RAY

9.7.5 POSITRON EMISSION TOMOGRAPHY

9.7.6 NUCLEAR MEDICINE

9.7.7 OPTICAL COHERENCE TOMOGRAPHY

9.7.8 ECHOCARDIOGRAPHY

9.7.9 OTHERS

9.8 OTHERS

10 EUROPE CLINICAL TRIAL IMAGING MARKET, BY END USER

10.1 OVERVIEW

10.2 CONTRACT RESEARCH ORGANIZATION

10.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES

10.4 MEDICAL DEVICE MANUFACTURERS

10.5 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES

10.6 OTHERS

11 EUROPE CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR

11.1 OVERVIEW

11.2 DIRECT SALES

11.3 TENDER SALES

12 EUROPE CLINICAL TRIAL IMAGING MARKET, BY REGION

12.1 EUROPE

12.1.1 GERMANY

12.1.2 FRANCE

12.1.3 U.K.

12.1.4 ITALY

12.1.5 SPAIN

12.1.6 SWITZERLAND

12.1.7 RUSSIA

12.1.8 NETHERLANDS

12.1.9 BELGIUM

12.1.10 TURKEY

12.1.11 REST OF EUROPE

13 EUROPE CLINICAL TRIAL IMAGING MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: EUROPE

14 SWOT ANALYSIS

15 COMPANY PROFILE

15.1 NAVITAS LIFE SCIENCES

15.1.1 COMPANY SNAPSHOT

15.1.2 COMPANY SHARE ANALYSIS

15.1.3 PRODUCT PORTFOLIO

15.1.4 RECENT DEVELOPMENTS

15.2 RESONANCE HEALTH ANALYTICAL SERVICES

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUE ANALYSIS

15.2.3 COMPANY SHARE ANALYSIS

15.2.4 PRODUCT PORTFOLIO

15.2.5 RECENT DEVELOPMENT

15.3 CLARIO

15.3.1 COMPANY SNAPSHOT

15.3.2 COMPANY SHARE ANALYSIS

15.3.3 PRODUCT PORTFOLIO

15.3.4 RECENT DEVELOPMENTS

15.4 PARAXEL

15.4.1 COMPANY SNAPSHOT

15.4.2 COMPANY SHARE ANALYSIS

15.4.3 PRODUCT PORTFOLIO

15.4.4 RECENT DEVELOPMENT

15.5 BIOTELEMETRY, A PHILIPS COMPANY

15.5.1 COMPANY SNAPSHOT

15.5.2 COMPANY SHARE ANALYSIS

15.5.3 PRODUCT PORTFOLIO

15.5.4 RECENT DEVELOPMENT

15.6 ICON PLC

15.6.1 COMPANY SNAPSHOT

15.6.2 REVENUE ANALYSIS

15.6.3 PRODUCT PORTFOLIO

15.6.4 RECENT DEVELOPMENTS

15.7 MEDIAN TECHNOLOGIES

15.7.1 COMPANY SNAPSHOT

15.7.2 REVENUE ANALYSIS

15.7.3 PRODUCT PORTFOLIO

15.7.4 RECENT DEVELOPMENT

15.8 PERSPECTUM

15.8.1 COMPANY SNAPSHOT

15.8.2 PRODUCT PORTFOLIO

15.8.3 RECENT DEVELOPMENTS

15.9 ANAGRAM 4 CLINICAL TRIALS

15.9.1 COMPANY SNAPSHOT

15.9.2 PRODUCT PORTFOLIO

15.9.3 RECENT DEVELOPMENT

15.1 CALYX

15.10.1 COMPANY SNAPSHOT

15.10.2 PRODUCT PORTFOLIO

15.10.3 RECENT DEVELOPMENT

15.11 IMAGE CORE LAB

15.11.1 COMPANY SNAPSHOT

15.11.2 PRODUCT PORTFOLIO

15.11.3 RECENT DEVELOPMENT

15.12 INVICRO. LLC. (A SUBSIDIARY OF KONICA MINOLTA)

15.12.1 COMPANY SNAPSHOT

15.12.2 REVENUE ANALYSIS

15.12.3 PRODUCT PORTFOLIO

15.12.4 RECENT DEVELOPMENTS

15.13 IXICO PLC

15.13.1 COMPANY SNAPSHOT

15.13.2 REVENUE ANALYSIS

15.13.3 PRODUCT PORTFOLIO

15.13.4 RECENT DEVELOPMENTS

15.14 QUOTIENT SCIENCES

15.14.1 COMPANY SNAPSHOT

15.14.2 PRODUCT PORTFOLIO

15.14.3 RECENT DEVELOPMENT

15.15 RADIANT SAGE LLC

15.15.1 COMPANY SNAPSHOT

15.15.2 PRODUCT PORTFOLIO

15.15.3 RECENT DEVELOPMENT

15.16 WIRB-COPERNICUS GROUP

15.16.1 COMPANY SNAPSHOT

15.16.2 PRODUCT PORTFOLIO

15.16.3 RECENT DEVELOPMENT

15.17 WORLDCARE CLINICAL

15.17.1 COMPANY SNAPSHOT

15.17.2 PRODUCT PORTFOLIO

15.17.3 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS

表格列表

TABLE 1 COST OF CLINICAL TRIAL PHASE 2 AND PHASE 3

TABLE 2 HUGE R&D COST IN THE U.S. FOR DIFFERENT PHASES

TABLE 3 EUROPE CLINICAL TRIAL IMAGING MARKET, BY PRODUCTS & SERVICES, 2020-2029 (USD MILLION)

TABLE 4 EUROPE SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 EUROPE SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCTS & SERVICES, 2020-2029 (USD MILLION)

TABLE 6 EUROPE SOFTWARE IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 EUROPE CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 8 EUROPE COMPUTED TOMOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 EUROPE MAGNETIC RESONANCE IMAGING IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 EUROPE ECHOCARDIOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 EUROPE NUCLEAR MEDICINE IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 EUROPE POSITRON EMISSION TOMOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 EUROPE X-RAY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 EUROPE ULTRASOUND IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 EUROPE OPTICAL COHERENCE TOMOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 EUROPE OTHERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 EUROPE CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 18 EUROPE ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 EUROPE ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 20 EUROPE NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 EUROPE NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 22 EUROPE CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 EUROPE CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 24 EUROPE ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 EUROPE ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 26 EUROPE DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 EUROPE DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 28 EUROPE HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 EUROPE HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 30 EUROPE OTHERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 EUROPE CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 32 EUROPE CONTRACT RESEARCH ORGANIZATION IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 EUROPE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 EUROPE MEDICAL DEVICE MANUFACTURERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 EUROPE ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 EUROPE OTHERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 37 EUROPE CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 38 EUROPE DIRECT SALES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 EUROPE TENDER SALES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 40 EUROPE CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 41 EUROPE CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 42 EUROPE SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 43 EUROPE CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 44 EUROPE CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 45 EUROPE ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 46 EUROPE NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 47 EUROPE ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 48 EUROPE CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 49 EUROPE DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 50 EUROPE HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 51 EUROPE CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 52 EUROPE CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 53 GERMANY CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 54 GERMANY SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 55 GERMANY CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 56 GERMANY CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 57 GERMANY ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 58 GERMANY NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 59 GERMANY ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 60 GERMANY CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 61 GERMANY DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 62 GERMANY HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 63 GERMANY CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 64 GERMANY CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 65 FRANCE CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 66 FRANCE SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 67 FRANCE CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 68 FRANCE CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 69 FRANCE ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 70 FRANCE NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 71 FRANCE ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 72 FRANCE CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 73 FRANCE DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 74 FRANCE HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 75 FRANCE CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 76 FRANCE CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 77 U.K. CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 78 U.K. SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 79 U.K. CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 80 U.K. CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 81 U.K. ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 82 U.K. NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 83 U.K. ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 84 U.K. CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 85 U.K. DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 86 U.K. HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 87 U.K. CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 88 U.K. CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 89 ITALY CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 90 ITALY CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 91 ITALY CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 92 ITALY CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 93 ITALY ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 94 ITALY NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 95 ITALY ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 96 ITALY CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 97 ITALY DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 98 ITALY HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 99 ITALY CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 100 ITALY CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 101 SPAIN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 102 SPAIN SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 103 SPAIN CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 104 SPAIN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 105 SPAIN ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 106 SPAIN NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 107 SPAIN ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 108 SPAIN CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 109 SPAIN DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 110 SPAIN HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 111 SPAIN CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 112 SPAIN CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 113 SWITZERLAND CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 114 SWITZERLAND SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 115 SWITZERLAND CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 116 SWITZERLAND CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 117 SWITZERLAND ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 118 SWITZERLAND NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 119 SWITZERLAND ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 120 SWITZERLAND CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 121 SWITZERLAND DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 122 SWITZERLAND HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 123 SWITZERLAND CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 124 SWITZERLAND CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 125 RUSSIA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 126 RUSSIA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 127 RUSSIA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 128 RUSSIA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 129 RUSSIA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 130 RUSSIA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 131 RUSSIA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 132 RUSSIA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 133 RUSSIA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 134 RUSSIA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 135 RUSSIA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 136 RUSSIA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 137 NETHERLANDS CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 138 NETHERLANDS SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 139 NETHERLANDS CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 140 NETHERLANDS CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 141 NETHERLANDS ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 142 NETHERLANDS NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 143 NETHERLANDS ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 144 NETHERLANDS CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 145 NETHERLANDS DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 146 NETHERLANDS HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 147 NETHERLANDS CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 148 NETHERLANDS CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 149 BELGIUM CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 150 BELGIUM SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 151 BELGIUM CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 152 BELGIUM CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 153 BELGIUM ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 154 BELGIUM NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 155 BELGIUM ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 156 BELGIUM CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 157 BELGIUM DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 158 BELGIUM HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 159 BELGIUM CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 160 BELGIUM CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 161 TURKEY CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 162 TURKEY SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 163 TURKEY CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 164 TURKEY CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 165 TURKEY ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 166 TURKEY NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 167 TURKEY ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 168 TURKEY CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 169 TURKEY DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 170 TURKEY HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 171 TURKEY CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 172 TURKEY CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 173 REST OF EUROPE CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

图片列表

FIGURE 1 EUROPE CLINICAL TRIAL IMAGING MARKET: SEGMENTATION

FIGURE 2 EUROPE CLINICAL TRIAL IMAGING MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE CLINICAL TRIAL IMAGING MARKET: DROC ANALYSIS

FIGURE 4 EUROPE CLINICAL TRIAL IMAGING MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE CLINICAL TRIAL IMAGING MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE CLINICAL TRIAL IMAGING MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE CLINICAL TRIAL IMAGING MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE CLINICAL TRIAL IMAGING MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 EUROPE CLINICAL TRIAL IMAGING MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE CLINICAL TRIAL IMAGING MARKET: SEGMENTATION

FIGURE 11 THE INCREASING NUMBER OF CONTRACT RESEARCH ORGANIZATION AND RISING R&D EXPENDITURE ARE EXPECTED TO DRIVE THE EUROPE CLINICAL TRIAL IMAGING MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 SERVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE CLINICAL TRIAL IMAGING MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE CLINICAL TRIAL IMAGING MARKET

FIGURE 14 WORLDWIDE BIOPHARMA COMPANIES R&D EXPENDITURE (IN USD MILLION)

FIGURE 15 THE MARKET GROWTH IN CLINICAL CRO (IN USD MILLIONS)

FIGURE 16 THE FUNCTION OF CRO

FIGURE 17 ESTIMATED NEW CANCER CASES, 2022

FIGURE 18 VALUE OF THE PHARMACEUTICAL SECTOR, WORLDWIDE, 2021 BY COUNTRY (IN MILLION U.S. DOLLARS)

FIGURE 19 EUROPE CLINICAL TRIAL IMAGING MARKET: BY PRODUCTS & SERVICES, 2021

FIGURE 20 EUROPE CLINICAL TRIAL IMAGING MARKET: BY PRODUCTS & SERVICES, 2022-2029 (USD MILLION)

FIGURE 21 EUROPE CLINICAL TRIAL IMAGING MARKET: BY PRODUCTS & SERVICES, CAGR (2022-2029)

FIGURE 22 EUROPE CLINICAL TRIAL IMAGING MARKET: BY PRODUCTS & SERVICES, LIFELINE CURVE

FIGURE 23 EUROPE CLINICAL TRIAL IMAGING MARKET: BY MODALITY, 2021

FIGURE 24 EUROPE CLINICAL TRIAL IMAGING MARKET: BY MODALITY, 2022-2029 (USD MILLION)

FIGURE 25 EUROPE CLINICAL TRIAL IMAGING MARKET: BY MODALITY, CAGR (2022-2029)

FIGURE 26 EUROPE CLINICAL TRIAL IMAGING MARKET: BY MODALITY, LIFELINE CURVE

FIGURE 27 EUROPE CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, 2021

FIGURE 28 EUROPE CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, 2022-2029 (USD MILLION)

FIGURE 29 EUROPE CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 30 EUROPE CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 31 EUROPE CLINICAL TRIAL IMAGING MARKET: BY END USER, 2021

FIGURE 32 EUROPE CLINICAL TRIAL IMAGING MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 33 EUROPE CLINICAL TRIAL IMAGING MARKET: BY END USER, CAGR (2022-2029)

FIGURE 34 EUROPE CLINICAL TRIAL IMAGING MARKET: BY END USER, LIFELINE CURVE

FIGURE 35 EUROPE CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, 2021

FIGURE 36 EUROPE CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, 2022-2029 (USD MILLION)

FIGURE 37 EUROPE CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, CAGR (2022-2029)

FIGURE 38 EUROPE CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, LIFELINE CURVE

FIGURE 39 EUROPE CLINICAL TRIAL IMAGING MARKET: SNAPSHOT (2021)

FIGURE 40 EUROPE CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2021)

FIGURE 41 EUROPE CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2022 & 2029)

FIGURE 42 EUROPE CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2021 & 2029)

FIGURE 43 EUROPE CLINICAL TRIAL IMAGING MARKET: BY PRODUCT AND SERVICES (2022-2029)

FIGURE 44 EUROPE CLINICAL TRIAL IMAGING MARKET: COMPANY SHARE 2021 (%)

查看详细信息 Right Arrow

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外,市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息,请请求分析师致电或下拉您的询问。

DBMR 研究团队使用的关键研究方法是数据三角测量,其中包括数据挖掘、数据变量对市场影响的分析和主要(行业专家)验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息,请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制,包括目标品牌的价格趋势分析、了解其他国家的市场(索取国家列表)、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表(事实手册)中的数据,或者可以帮助您根据报告中的数据集创建演示文稿。

Testimonial